Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AVENUE THERAPEUTICS, INC.ATXI · Entity 8537 | Director · Chief Executive Officer | September 23, 2024 | September 25, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AVENUE THERAPEUTICS, INC.
Report date September 23, 2024 · Filed September 25, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCK, PAR VALUE $0.0001SEC Table I · non-derivative | Direct | 170,000 |
Reported balance
After 2024-09-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-09-23 · Grant · Acquired 170,000 · Balance 170,000 F1: Represents an award of 170,000 restricted stock units which will vest in equal installments at September 30, 2024, December 31, 2024, September 23, 2025, and September 23, 2026. The shares underlying the restricted stock units will not be settled until the earlier of the tenth business day of January of the year following certain terminations of service of the Reporting Person from the Issuer and Change in Control events (as defined in the Avenue Therapeutics, Inc. 2015 Incentive Plan); the amount will be distributed in the form of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of 170,000 restricted stock units which will vest in equal installments at September 30, 2024, December 31, 2024, September 23, 2025, and September 23, 2026. The shares underlying the restricted stock units will not be settled until the earlier of the tenth business day of January of the year following certain terminations of service of the Reporting Person from the Issuer and Change in Control events (as defined in the Avenue Therapeutics, Inc. 2015 Incentive Plan); the amount will be distributed in the form of the Issuer's common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 23, 2024 Filed Sep 25, 2024 16:55 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 170,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-102836 · tm2424771-4_4seq1.xml · nonDerivative · entry 1 MacLean Alexandra · CIK 0001940880 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,000 F1 · shares: Represents an award of 170,000 restricted stock units which will vest in equal installments at September 30, 2024, December 31, 2024, September 23, 2025, and September 23, 2026. The shares underlying the restricted stock units will not be settled until the earlier of the tenth business day of January of the year following certain terminations of service of the Reporting Person from the Issuer and Change in Control events (as defined in the Avenue Therapeutics, Inc. 2015 Incentive Plan); the amount will be distributed in the form of the Issuer's common stock. F1 · balance_after: Represents an award of 170,000 restricted stock units which will vest in equal installments at September 30, 2024, December 31, 2024, September 23, 2025, and September 23, 2026. The shares underlying the restricted stock units will not be settled until the earlier of the tenth business day of January of the year following certain terminations of service of the Reporting Person from the Issuer and Change in Control events (as defined in the Avenue Therapeutics, Inc. 2015 Incentive Plan); the amount will be distributed in the form of the Issuer's common stock. Read SEC document |
| June 29, 2023 Filed Jul 3, 2023 13:05 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantEmployee stock option (right to buy) · Derivative | 800,000 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001104659-23-077528 · tm2320376-1_4seq1.xml · derivative · entry 1 MacLean Alexandra · CIK 0001940880 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Stock · 800,000 shares Expires 2033-06-29 F1 · derivative.exercise_date: The option vests in accordance with the following schedule: (i) 25% of the shares subject to the option vest on August 1, 2023; (ii) 25% of the shares subject to the option vest on August 1, 2024; (iii) 25% of the shares subject to the option vest on August 1, 2025; and (iv) 25% of the shares subject to the option vest on August 1, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.